President’s Letter | December 2021 From the Desk of Samantha Guild Here at AIM at Melanoma, we started 2021 talking about Hope and are ending…
The Importance of Peer Support when Battling Melanoma By Mara Klecker In recent months, the texts back and forth between Allie Thomas and Lisa Billings have revolved…
Melanoma by the State: North Carolina North Carolina is known as the Tar Heel state, and the term “tar heel” dates back to the state’s…
From Survivors to Advocates: Two Leaders are Pushing for Progress in Canada and Around the World by Mara Klecker Natalie Richardson, of British Columbia, Canada, hasn’t forgotten the fear and uncertainty she felt after her…
In One Woman’s Memory, a Tradition Helps Create a Community of Support by Mara Klecker The idea for a walk to raise funds and awareness for melanoma came to Tricia Edwards in…
Shop Amazon Smile This Holiday Season We continually try to answer the question that so many of you ask us: How can I help? Here…
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
THE GRATITUDE GALA: AIM’s 3rd Annual No Show Gala & Online Auction What is a “no-show” gala? AIM at Melanoma’s Third Annual No Show Gala & Auction is a unique fundraiser that…
Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
Apr. 19, 2026 KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
Apr. 10, 2026 FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients